These novel Fora, in WEF-style format, will bring together corporate participants, neuroscientists and clinicians with outstanding experience in “hottest” research topics in the field of neurodegeneration to discuss the impact of newest preclinical results and cutting edge clinical findings on understanding and treatment development of neurodegenerative disorders. The objective is to exchange novel insights, challenges and solutions on the joint path forward to defining the future of Alzheimer’s and Parkinson’s therapeutics.

Each forum will be a moderated discussion with maximum 3 minutes introduction statement from each participant followed by questions from the audience. The forum is also open for journalists from different media, including lay press in and may report on progress made by the leaders in this field.

Forum Date & Title

Co-Moderators

Discussants

Wednesday, March 6, 2024 | 14:30–15:30

BLOOD-BASED BIOMARKERS (BBM) – HOW DO THEY RELATE TO CSF, DIGITAL TOOLS, AND IMAGING BIOMARKERS?

Melissa Murray
Oskar Hansson

Michael Pontecorvo
Charlotte Teunissen
Agneta Nordberg
Pallavi Sachdev
Danielle Graham
Howard Fillit

Wednesday, March 6, 2024 | 15:35–16:35

IMMUNOTHERAPIES IN AD – WHAT ARE THE PRESENT CHALLENGES AND FUTURE BENEFITS?

Robert Vassar
Suzanne Hendrix

Chad Swanson
John Sims (Eli Lilly)
Philip Scheltens
Takeshi Iwatsubo
Stephen Salloway

Thursday, March 7, 2024 | 17:30–18:30

NEW INSIGHTS IN THE DEVELOPMENT OF BIOMARKERS, IMAGING, AND THERAPY OF ALPHA-SYNUCLEIN, LRKK2, AND GBA PATHOLOGIES

Jamie Eberling
Walter Koroshetz

Fabrizio Stocchi
Werner Poewe
Pamela McLean
Maria Maccecchini
John Alam
Gennaro Pagano
Zdenek Berger

Friday, March 8, 2024 | 16:20–17:20

TRANSLATIONAL DRUG DEVELOPMENT IN AD (PHASE I-III) AND RELEVANCE FOR TREATMENT AND DISEASE MODIFICATION – WHAT COULD BE PROMISING STRATEGIES?

Jeffrey Cummings
Howard Fillit

Suzanne Hendrix
Luka Kulic
Jaren Landen
Frank Longo
Miia Kivipelto
Chad Swanson

Friday, March 8, 2024 | 17:30–18:30

ANTI-TAU THERAPIES IN CLINICAL TRIALS – WHAT ARE THE CHALLENGES AND OPPORTUNITIES FOR A RATIONAL THERAPY?

Marc Diamond
Luc Buee

Claude Wischik
Virginia Lee
Bradley Hyman
Larisa Reyderman
Melanie Schulman

Saturday, March 9, 2024 | 14:10–15:10

THERAPY FOR AD, PD & LBD: MAJOR ETIOLOGICAL UNANSWERED QUESTIONS, MISSING TARGETS, AND FUNCTIONAL MARKERS

Manfred Windisch
Cynthia Lemere

Todd Golde
Diane Bovenkamp
Michael Heneka
Jie Shen
Tomislav Babic

Saturday, March 9, 2024 | 15:20–16:20

DRUG DEVELOPMENT & BIOMARKERS IN RARE CNS DISEASES (ALS, FTD): FROM BASICS TOWARD APPROVAL – WHAT COULD BE PROMISING STRATEGIES?

Laura Ranum
Angela Genge

Klaus Gerwert
Toby Ferguson
Manuela Neumann
Maria Grazia Spillantini
Tamara Shiner